Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Sandoz Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (682)
Cancellation by sponsor (321)
Prescription medicine registration (54)
Section 14, TGO91 consent (17)
Cancellation or suspension (8)
Australian Public Assessment Report (AusPAR) (4)
Prescription medicine decision summary (1)

Date

2024 (82)
2023 (78)
2022 (67)
2021 (121)
2020 (153)
2019 (53)
2018 (60)
2017 (50)
2016 (4)
2015 (39)
2014 (20)
2013 (24)
2012 (13)
2011 (51)
2010 (47)
2009 (37)
2008 (27)
2007 (21)
2006 (21)
2005 (54)
2004 (12)
2003 (10)
2002 (10)
2001 (6)
2000 (5)
1999 (5)
1998 (9)
1997 (4)
1991 (3)

Results for "[search-keyword]"

Search

Sponsor content

1087 result(s) found, displaying 31 to 40

DOXORUBICIN EBEWE doxorubicin hydrochloride 200mg/100mL injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Sandoz Pty Ltd
DOXORUBICIN EBEWE doxorubicin hydrochloride 100mg/50mL injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Sandoz Pty Ltd
DOXORUBICIN EBEWE doxorubicin hydrochloride 50mg/25mL injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Sandoz Pty Ltd
DOXORUBICIN EBEWE doxorubicin hydrochloride 10mg/5mL injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Sandoz Pty Ltd
CEFTRIAXONE SANDOZ ceftriaxone 2g (as sodium) powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Sandoz Pty Ltd
CEFTRIAXONE SANDOZ ceftriaxone 1g (as sodium) powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Sandoz Pty Ltd
LENALIDOMIDE SANDOZ lenalidomide 20 mg capsule blister pack (410031)

6 March 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LENALIDOMIDE SANDOZ lenalidomide 20 mg capsule blister pack.
LENALIDOMIDE SANDOZ lenalidomide 7.5 mg capsule blister pack (410030)

6 March 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LENALIDOMIDE SANDOZ lenalidomide 7.5 mg capsule blister pack.
LENALIDOMIDE SANDOZ lenalidomide 2.5 mg capsule blister pack (410017)

6 March 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LENALIDOMIDE SANDOZ lenalidomide 2.5 mg capsule blister pack.
AZATHIOPRINE GH azathioprine 50mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Sandoz Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.